Merck (MRK) Perks
Merck’s (MRK) sales for the last quarter were $6.1 billion, an increase of 6% from the second quarter of 2006. Net income for the second quarter of 2007 was $1,676.4 million, compared to $1,499.3 million in the same quarter a…
Merck’s (MRK) sales for the last quarter were $6.1 billion, an increase of 6% from the second quarter of 2006. Net income for the second quarter of 2007 was $1,676.4 million, compared to $1,499.3 million in the same quarter a year ago.
The company raised full-year 2007 guidance and now anticipates EPS range of $3.00 to $3.10.
WORLDWIDEPRODUCT 2007 SALES----------------------------------- ------------------------------SINGULAIR (Respiratory) $4.0 to $4.3 billionCOZAAR/HYZAAR (Hypertension) $3.2 to $3.5 billionVaccines (as recorded by Merck &Co., Inc.) $3.9 to $4.3 billionFOSAMAX (Osteoporosis) $2.8 to $3.1 billionZOCOR (Cholesterol modifying) $0.6 to $0.9 billionOther reported products* $5.6 to $5.9 billion
Douglas A McIntyre
Contact [email protected] for any questions or corrections.
